NADIA WEIDNER: Open Payments
NPI 1568143931 · NEW KENSINGTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,072 in 59 payments from 9 companies in 2025. Trend: 2023 $47 · 2024 $523 · 2025 $1,072
Food & beverage: $1,072
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $410 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $236 |
| Supernus Pharmaceuticals, Inc. | 1 | $104 |
| Otsuka America Pharmaceutical, Inc. | 4 | $91 |
| Vanda Pharmaceuticals Inc. | 3 | $89 |
| Alkermes, Inc. | 2 | $59 |
| Lundbeck LLC | 3 | $49 |
| Janssen Pharmaceuticals, Inc | 1 | $21 |
| Neurocrine BioSciences, Inc. | 1 | $14 |
Products named: VRAYLAR, CAPLYTA, REXULTI, Qelbree, FANAPT, LYBALVI, INVEGA SUSTENNA, ABILIFY MAINTENA.
Industry payments across PA — which companies pay providers there.
